Recently, the epidemic prevention and control work in Shanghai has entered a critical stage. The medical personnel, grassroots Party members, community workers and volunteers have been engaged in the frontline to build a solid fortress for the prevention and control of the epidemic and overcome the difficulties together, fighting the epidemic with one heart to protect the homeland of Shanghai. For these front-line workers, medical protective clothing, medical masks and other protective supplies are the most important and most urgent supplies for epidemic prevention.

 Sumitomo Pharma (Suzhou) Co., Ltd.(Suzhou) Co., Ltd. (hereinafter referred to as "Sumitomo Pharma (Suzhou) Co., Ltd.") paid close attention to the development of the epidemic. On the premise of ensuring no contact and zero infection, Sumitomo Pharma (Suzhou) Co., Ltd. quickly coordinated internal and external resources and quickly mobilized transportation vehicles to donate more than 1,700 sets of medical protective clothing worth about RMB100,000 to the Dapuqiao Subdistrict Office in Huangpu District on April 8, 2022 as a modest contribution to community workers and grassroots volunteers, helping ensure their safety and health and appreciating their selfless contributions in the fight against the epidemic.

In this "battle field without the smoke of gunpowder", Sumitomo Pharma (Suzhou) Co., Ltd. has responded positively to the requirements of local governments to prevent the epidemic and promptly adopted a home office model in its Shanghai office to protect the health of employees. At the same time, the company adheres to the "patient-oriented" concept to ensure the normal operation of production lines under the premise of epidemic prevention and health, and continues to provide patients with high-quality innovative drugs to protect their health.

Sumitomo Pharma (Suzhou) Co., Ltd. CEO Yoshitaka Koketsu said the COVID-19 epidemic is a major public health problem faced by the world. In China, countless medical personnel, community workers and volunteers are working day and night. It has become a common goal of all sectors of society to firmly contain the spread of this outbreak. As a social corporate citizen in China,  Sumitomo Pharma (Suzhou) Co., Ltd.is deeply concerned about the prevention and control of the epidemic. The company understands the importance of supplying epidemic prevention materials and is actively taking action. We express our highest respect to front-line workers.  Sumitomo Pharma (Suzhou) Co., Ltd.will also closely monitor the development of the epidemic and actively fulfill its social responsibility to fight the epidemic with one heart, hoping that the epidemic will be overcome and people will be safe.

Based in China for nearly 30 years, Sumitomo Pharma (Suzhou) Co., Ltd. has always been active in fulfilling its social responsibility and has donated supplies and cash worth more than RMB1.1 million to contribute to the prevention and control of the epidemic since the outbreak of COVID-19 pneumonia.

Like the mountain range that stretches before you and me, let's share the same trials and hardships together. We believe that with the help of all sectors of society, Shanghai will soon end the "cold in late spring" of the epidemic and return to prosperity and normal life.

About Sumitomo Pharma (Suzhou) Co., Ltd.:

Since its establishment in China in the 1990s, Sumitomo Pharma (Suzhou) Co., Ltd. has developed China as one of its key market operating bases. The company has introduced advanced international manufacturing technologies to China and has provided high-quality products and pharmaceutical solutions in the fields of central nervous system disorders,  infection prevention, cardiovascular diseases and digestive diseases, benefiting numerous patients over the years. At the same time, the company also actively participates in various social welfare projects and fully supports the further development of health care in China. Sumitomo Pharma (Suzhou) Co., Ltd. adheres to its corporate mission of "Based in China, we will continue to create and contribute new value to human health and happiness", and will continue to provide high-quality pharmaceutical products with a "patient-oriented" mission to contribute to the long-term development of China's medical industry.

SMPC-NP-CI-22-04-0003